Literature DB >> 28132226

P003. NSAIDs for symptomatic treatment of headache.

Giannapia Affaitati1, Paolo Martelletti2, Mariangela Lopopolo3, Claudio Tana4, Francesca Massimini5, Francesco Cipollone3, Domenico Lapenna3, Maria Adele Giamberardino3, Raffaele Costantini6.   

Abstract

Entities:  

Year:  2015        PMID: 28132226      PMCID: PMC4715195          DOI: 10.1186/1129-2377-16-S1-A162

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   7.277


× No keyword cloud information.

Background and aims

Clinical observations suggest that the use of non-steroidal anti-inflammatory drugs (NSAIDs) for symptomatic treatment of headache is not in line with recommendations by international guidelines [1]. The aim of the study was to evaluate NSAIDs use for episodic headache at the Headache Centre of the Chieti University in the period: January 2000-February 2013.

Methods

A retrospective evaluation was carried out on 6,443 records of episodic migraine (n=2,330), tension-type headache (TTH) (n=807) and migraine + TTH (n=3,306) sufferers relative to NSAID use for the acute attack: type of NSAID/s; uni- or poly-therapy (one or more NSAID/s in different attacks) and NSAID efficacy (subjective scale: complete (C), partial (P) or absent (A) pain relief at 2 hours), at the first visit and 1-year follow-up.

Results

In migraine patients, 80% had been NSAID users in the past year. The three most frequently employed molecules were: nimesulide (57%), ketoprofen (25%) and ibuprofen (24%). Complete vs. incomplete/absent efficacy was significantly higher for all three (p < 0.0001). NSAIDs were replaced with triptans in 53% of the patients at the first visit; after 1 year: a significant spontaneous return to NSAIDs occurred in 56% of the cases (p < 0.0005) for inadequate efficacy/side effects (62%) or difficulty in obtaining prescription (38%) of triptans from the family doctor. In TTH patients, 90% were NSAID users; preferences were: nimesulide (48%), ketoprofen (47%) and diclofenac (19%); complete vs. incomplete/absent efficacy was significantly higher for the first two (p < 0.02). Replacement with analgesics was performed in 24% of the patients at the first visit; at one-year follow-up a spontaneous return to NSAIDs occurred in 29% of the cases for inadequate efficacy of the non-NSAID therapy. In Migraine + TTH patients who were not able to distinguish the nature of their attack at the beginning of the pain, 89% were NSAID users; the three most frequently employed molecules were: nimesulide (44%), ibuprofen (42%) and ketoprofen (38%); complete vs. incomplete/absent efficacy was significantly higher for all three (0.001 < p < 0.0001). Replacement with analgesics was prescribed to 31% of the patients at the first visit; at one-year follow-up a spontaneous return to NSAIDs occurred in 37% of them for inadequate efficacy of the non-NSAID therapy.

Conclusions

NSAID use in episodic headache is higher than could be hypothesized based on guidelines [2]. NSAID role/efficacy, particularly in migraine, should be better understood. A higher degree of sensitization towards different treatment options for headache should also be promoted in the medical environment [3]. Written informed consent to publish was obtained from the patient(s).
  3 in total

1.  Symptomatic treatment of migraine: when to use NSAIDs, triptans, or opiates.

Authors:  Frederick R Taylor; Robert G Kaniecki
Journal:  Curr Treat Options Neurol       Date:  2011-02       Impact factor: 3.598

2.  Pattern of NSAID use in the Italian general population: a questionnaire-based survey.

Authors:  Domenico Motola; Alberto Vaccheri; Maria Chiara Silvani; Elisabetta Poluzzi; Ambrogio Bottoni; Fabrizio De Ponti; Nicola Montanaro
Journal:  Eur J Clin Pharmacol       Date:  2004-10-26       Impact factor: 2.953

Review 3.  COX inhibitors for the treatment of migraine.

Authors:  Stephen D Silberstein; Jessica C Stirpe
Journal:  Expert Opin Pharmacother       Date:  2014-07-10       Impact factor: 3.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.